[Panniculitis during BRAF inhibitor and/or MEK inhibitor therapy: A new case report and literature review].

CONCLUSION: When panniculitis occurs during BRAF±MEK inhibitor therapy, the causal role of the TT must be considered after full etiological investigation. It is essential to determine whether a causal relationship exists in order to avoid unwarranted cessation of treatment.
PMID: 32948319 [PubMed - as supplied by publisher]

Source: Annales de Dermatologie et de Cenereologie - September 14, 2020 Category: Dermatology Authors: Piroth M, Frénard C, Eugène-Lamer J, Dreno B, Quéreux G Tags: Ann Dermatol Venereol Source Type: research